Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study.

Carcinoma, Hepatocellular Cisplatin / therapeutic use Cohort Studies Humans Infusions, Intra-Arterial Liver Neoplasms Retrospective Studies
Hepatic arterial infusion chemotherapy Hepatocellular carcinoma Macrovascular invasion Radiation therapy

Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
02 Jun 2022
Historique:
received: 06 12 2021
accepted: 24 05 2022
entrez: 2 6 2022
pubmed: 3 6 2022
medline: 7 6 2022
Statut: epublish

Résumé

Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis. This study aimed to determine if one-shot cisplatin (CDDP) chemotherapy via hepatic arterial infusion (HAI) combined with radiation therapy (RT) prior to systemic chemotherapy could improve the outcomes of these patients. This study consisted of 32 HCC patients with the following eligibility criteria: (i) portal vein invasion 3/4 and/or hepatic vein invasion 2/3; (ii) received one-shot CDDP via HAI; (iii) received RT for MVI, (iv) a Child-Pugh score ≤ 7; and (v) an Eastern Clinical Oncology Group Performance Status score of 0 or 1. To determine the therapeutic effect, we collected information on patient characteristics and took contrast-enhanced computed tomography at the start of the therapy and every 2 to 4 months after the start of therapy. We evaluated the overall response of the tumor and tumor thrombosis according to modified Response Evaluation Criteria in Solid Tumors. We assessed patient data using the Mann-Whitney U and Fisher exact tests and evaluated overall survival and progression-free survival using the log-rank test. The overall response rate at the first evaluation performed a median of 1.4 weeks after HAI was 16% for the main intrahepatic tumor and 59% for the MVI. The best responses were the same as those of the first-time responses. The duration of median survival was 8.6 months, and progression-free survival of the main intrahepatic tumor was 3.2 months. Predictive factors for overall survival were the relative tumor volume in the liver and the first therapeutic response of MVI. There were no severe adverse events or radiation-induced hepatic complications. One-shot CDDP via HAI and RT were well tolerated and showed immediate and favorable control of MVI. Thus, this combination shows potential as a bridging therapy to systemic chemotherapy.

Sections du résumé

BACKGROUND BACKGROUND
Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis. This study aimed to determine if one-shot cisplatin (CDDP) chemotherapy via hepatic arterial infusion (HAI) combined with radiation therapy (RT) prior to systemic chemotherapy could improve the outcomes of these patients.
METHODS METHODS
This study consisted of 32 HCC patients with the following eligibility criteria: (i) portal vein invasion 3/4 and/or hepatic vein invasion 2/3; (ii) received one-shot CDDP via HAI; (iii) received RT for MVI, (iv) a Child-Pugh score ≤ 7; and (v) an Eastern Clinical Oncology Group Performance Status score of 0 or 1. To determine the therapeutic effect, we collected information on patient characteristics and took contrast-enhanced computed tomography at the start of the therapy and every 2 to 4 months after the start of therapy. We evaluated the overall response of the tumor and tumor thrombosis according to modified Response Evaluation Criteria in Solid Tumors. We assessed patient data using the Mann-Whitney U and Fisher exact tests and evaluated overall survival and progression-free survival using the log-rank test.
RESULTS RESULTS
The overall response rate at the first evaluation performed a median of 1.4 weeks after HAI was 16% for the main intrahepatic tumor and 59% for the MVI. The best responses were the same as those of the first-time responses. The duration of median survival was 8.6 months, and progression-free survival of the main intrahepatic tumor was 3.2 months. Predictive factors for overall survival were the relative tumor volume in the liver and the first therapeutic response of MVI. There were no severe adverse events or radiation-induced hepatic complications.
CONCLUSIONS CONCLUSIONS
One-shot CDDP via HAI and RT were well tolerated and showed immediate and favorable control of MVI. Thus, this combination shows potential as a bridging therapy to systemic chemotherapy.

Identifiants

DOI: 10.1186/s12876-022-02359-x PMID: 35655156 PMC: PMC9161561
pubmed: 35655156
doi: 10.1186/s12876-022-02359-x
pii: 10.1186/s12876-022-02359-x
pmc: PMC9161561
doi:

Substances chimiques

Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

275

Informations de copyright

© 2022. The Author(s).

Références

Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Liver Cancer. 2020 Aug;9(4):367-377
pubmed: 32999864
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S94-100
pubmed: 20171524
Cancer. 2002 Jan 15;94(2):435-42
pubmed: 11900229
J Hepatol. 2013 Apr;58(4):724-9
pubmed: 23178708
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
J Clin Oncol. 2006 May 10;24(14):2137-50
pubmed: 16682732
Br J Cancer. 2005 Sep 5;93(5):557-64
pubmed: 16106266
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432
pubmed: 29631810
J Gastroenterol. 2006 Feb;41(2):100-6
pubmed: 16568368
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Radiother Oncol. 2007 Sep;84(3):266-71
pubmed: 17716760
Gastrointest Cancer Res. 2011 Mar;4(2):40-4
pubmed: 21673874
Aliment Pharmacol Ther. 2011 Nov;34(10):1193-201
pubmed: 21958438
Hepatol Res. 2018 Dec;48(13):1118-1130
pubmed: 30030881
Cancer. 2008 Sep 1;113(5):995-1003
pubmed: 18615601
Ann Oncol. 2016 Nov;27(11):2090-2096
pubmed: 27573564
J Hepatol. 2012 Apr;56(4):886-92
pubmed: 22173160
J Gastroenterol. 2009;44(5):492-502
pubmed: 19330281
Cancer. 2005 Jun 1;103(11):2419-26
pubmed: 15822130
Cancer. 2006 May 1;106(9):1990-7
pubmed: 16565970
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Cancer. 1997 May 15;79(10):1890-6
pubmed: 9149014
Hepatol Res. 2015 Jun;45(6):607-17
pubmed: 25052365
AJR Am J Roentgenol. 1996 Sep;167(3):759-68
pubmed: 8751696
Liver Cancer. 2021 Apr;10(2):151-160
pubmed: 33977091
J Surg Oncol. 2002 Jul;80(3):143-8
pubmed: 12115797
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Liver Int. 2007 Nov;27(9):1209-16
pubmed: 17919232
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Oncology. 2018;94(4):215-222
pubmed: 29428943

Auteurs

Kensuke Naruto (K)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Tomokazu Kawaoka (T)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kenichiro Kodama (K)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yutaro Ogawa (Y)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kei Amioka (K)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yuki Yoshikawa (Y)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Chihiro Kikukawa (C)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yousuke Suehiro (Y)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kenji Yamaoka (K)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yuwa Ando (Y)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yumi Kosaka (Y)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Shinsuke Uchikawa (S)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Takashi Nakahara (T)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Eisuke Murakami (E)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Atsushi Ono (A)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Takuro Uchida (T)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Masami Yamauchi (M)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Wataru Okamoto (W)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Shoichi Takahashi (S)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Michio Imamura (M)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Keigo Chosa (K)

Diagnostic Radiology, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kazuo Awai (K)

Diagnostic Radiology, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Katsumaro Kubo (K)

Therapeutic Radiology, Institute and Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yasushi Nagata (Y)

Therapeutic Radiology, Institute and Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kazuaki Chayama (K)

Research Center for Hepatology and Gastroenterology, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Institute of Physical and Chemical Research (RIKEN) Center for Integrative Medical Sciences, 1-7-22, Suehiro, Tsurumi-ku, Yokohama, 230-0045, Japan.

Hiroshi Aikata (H)

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. aikata@hiroshima-u.ac.jp.
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. aikata@hiroshima-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Efficacy and safety of chemoradiation therapy...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du platine › Cisplatine › Efficacy and safety of chemoradiation therapy...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Efficacy and safety of chemoradiation therapy...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy and safety of chemoradiation therapy...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Perfusions parentérales › Perfusions artérielles › Efficacy and safety of chemoradiation therapy...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Efficacy and safety of chemoradiation therapy...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Efficacy and safety of chemoradiation therapy...